ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study

Shi, Yuankai*; Chen, Gongyan; Wang, Xiang; Liu, Yunpeng; Wu, Lin; Hao, Yanrong; Liu, Chunling; Zhu, Shuyang; Zhang, Xiaodong; Li, Yuping; Liu, Jiwei; Cao, Lejie; Cheng, Ying; Zhao, Hui; Zhang, Shucai; Zang, Aimin; Cui, Jiuwei; Feng, Jian; Yang, Nong; Liu, Fei; Jiang, Yong; Gu, Chuan吉林大学; 南通大学; 哈尔滨医科大学; 中国医科大学; 中国医学科学院; 中国医学科学院北京协和医院; 1
Journal of Thoracic Oncology2022-11DOI: 10.1016/j.jtho.2022.07.1143
15被引14阅读
引用收藏
分享

摘要

Introduction: Furmonertinib (AST2818) is a pan-EGFR tyrosine kinase inhibitor with central nervous system (CNS) antitumor activity. We report the CNS efficacy of furmo-nertinib compared with gefitinib in untreated EGFR-sensi-tizing mutation-positive NSCLC from the FURLONG study.Methods: FURLONG was a randomized, double-blind, phase 3 study conducted in 55 hospitals in the People's Republic of China. Patients 1:1 randomly received furmonertinib 80 mg once daily or gefitinib 250 mg once daily treatment. At screening, all the patients underwent brain imaging exam-ination. Patients with asymptomatic steady CNS metastases at baseline constituted this preplanned CNS subgroup analysis.Results: A total of 358 patients were enrolled in the FURLONG study. In the 133 (37%) patients who had measurable or nonmeasurable CNS lesions, CNS progression-free survival was 20.8 months (95% confi-dence interval [CI]: 15.2-25.3) in the furmonertinib group and 9.8 months (95% CI: 7.2-18.0) in the gefitinib group (hazard ratio = 0.40 [95% CI: 0.23-0.71], p = 0.0011). In the 60 patients (17%) who had measurable CNS lesions, CNS objective response rate was 91% (95% CI: 72-99) with furmonertinib and 65% (95% CI: 48-80) with gefitinib (OR = 6.82 [95% CI: 1.23-37.67], p = 0.0277). The least -square mean of CNS depth of response was 62% (95% CI: 51-72) in the furmonertinib group and 39% (95% CI: 30- 47) in the gefitinib group, the mean difference was 23% (95% CI: 10-37, p = 0.0011). Conclusions: Furmonertinib first-line treatment was found to have superior efficacy in CNS progression-free survival, CNS objective response rate, and CNS depth of response compared with gefitinib in patients with EGFR-mutated NSCLC with CNS metastases.

学科与关键词

关键词
NSCLCEGFRFurmonertinibAST2818CNS
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Journal of Thoracic Oncology
发表日期
2022-11
卷期
第 17 卷, 第 11 期
页码
1297-1305
DOI
10.1016/j.jtho.2022.07.1143
语言
ENGLISH
期刊等级
1区
成果收录
SCIE
资助标注
Shanghai Allist Pharmaceuticals; China National Major Project for New Drug Innovation [2017ZX09304015]

作者

  • S

    Shi, Yuankai (通讯) (第一作者)

    chinese acad med sci · peking union med coll

  • C

    Chen, Gongyan

    harbin med univ

查看全部 22 位作者收起作者
  • W

    Wang, Xiang

  • L

    Liu, Yunpeng

    china med univ

  • W

    Wu, Lin

    2 · hunan canc hosp

  • H

    Hao, Yanrong

    peoples hosp guangxi zhuang autonomous reg

  • L

    Liu, Chunling

    xinjiang med univ

  • Z

    Zhu, Shuyang

    xuzhou med coll

  • Z

    Zhang, Xiaodong

    nantong canc hosp

  • L

    Li, Yuping

    1 · wenzhou med univ

  • L

    Liu, Jiwei

    1 · dalian med univ

  • C

    Cao, Lejie

    1 · ustc

  • C

    Cheng, Ying

  • Z

    Zhao, Hui

    anhui univ

  • Z

    Zhang, Shucai

    beijing chest hosp · capital med univ

  • Z

    Zang, Aimin

    hebei univ

  • C

    Cui, Jiuwei

    jilin univ

  • F

    Feng, Jian

    nantong univ

  • Y

    Yang, Nong

    hunan canc hosp

  • L

    Liu, Fei

  • J

    Jiang, Yong

  • G

    Gu, Chuan

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417